October 11, 2021

Rethymic® (allogenic processed thymus tissue-agdc) has been approved as a one-time treatment for congenital athymia in pediatric patients.

  • Congenital athymia is a rare immune disorder that occurs when a person is born without a thymus This gland is critical to proper function of the immune system. Children born without it may suffer from frequent life-threatening infections and often do not survive beyond two years of age.
  • Rethymic is the first treatment of its kind to be approved by the U.S. FDA. It consists of donor- derived, lab-cultured thymus tissue used to improve immune function.
  • Manufactured by Enzyvant, Rethymic is administered via a surgical implantation. The dose is calculated at the manufacturing facility, and the amount of Rethymic provided for the procedure is customized to the specific patient.
  • Rethymic has a wholesale acquisition cost (WAC) of $2,729,500 per implant.
May 1, 2022

Brand Medications with Generic Alternatives Anticipated to be Approved in May

Read More
April 25, 2022

Veklury Approved to Treat COVID-19 in Younger Patient Population

Read More
April 22, 2022

Pfizer Recalls Five Lots of Accupril

Read More
April 21, 2022

Zerbaxa Now Indicated for Children

Read More